ArticleBlood2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 86 citations in OpenAlex.
- Daratumumab plus bortezomib and dexamethasone (Dara-VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light-chain amyloidosis: Long-term follow-up results from a prospective phase 2 study.British journal of haematology · 2026Trial
- Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.Annals of hematology · 2023Trial
- A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.American journal of hematology · 2026Article
- Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss.Antibodies (Basel, Switzerland) · 2026Review
- Management of relapsed/refractory AL amyloidosis.Blood advances · 2026Review
- Bortezomib combined with autologous stem cell transplantation overcomes cytogenetic abnormalities in AL amyloidosis.International journal of hematology · 2026Article
- Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era.HemaSphere · 2025Article
- Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival.Annals of hematology · 2025Article
- Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.Annals of hematology · 2025Article
- Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.Journal of clinical medicine · 2024Review
- Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.Haematologica · 2024Article
- Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition).Frontiers in pharmacology · 2024Review
- Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Diagnosis and Treatment of AL Amyloidosis.Drugs · 2023Review
- Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis.Therapeutics and clinical risk management · 2023Review
- Efficacy and safety of intravenous daratumumab-based treatments for AL amyloidosis: a systematic review and meta-analysis.Cancer cell international · 2022Review
- Immunotherapy in AL Amyloidosis.Current treatment options in oncology · 2022Review
- IFNγ regulates NAD+ metabolism to promote the respiratory burst in human monocytes.Blood advances · 2022Article
- Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).Journal of personalized medicine · 2022Article
- [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Daratumumab has shown promising first results in systemic amyloid light-chain (AL) amyloidosis. We analyzed a consecutive series of 168 patients with advanced AL receiving either daratumumab/dexamethasone (DD, n = 106) or daratumumab/bortezomib/dexamethasone (DVD, n = 62). DD achieved a remission rate (RR) of 64% and a very good hematologic remission (VGHR) rate of 48% after 3 months. Median hematologic event-free survival (hemEFS) was 11.8 months and median overall survival (OS) was 25.6 months. DVD achieved a 66% RR and a 55% VGHR rate. Median hemEFS was 19.1 months and median OS had not been reached. Cardiac organ responses were noted in 22% with DD and 26% with DVD after 6 months. Infectious complications were common (Common Terminology Criteria [CTC] grade 3/4: DD 16%, DVD 18%) and likely related to a high rate of lymphocytopenia (CTC grade 3/4: DD 20%, DVD 17%). On univariable analysis, hyperdiploidy and gain 1q21 conferred an adverse factor for OS and hemEFS with DD, whereas translocation t(11;14) was associated with a better hemEFS. N-terminal prohormone of brain natriuretic peptide >8500 ng/L could not be overcome for survival with each regimen. Multivariable Cox regression analysis revealed plasma cell dyscrasia (difference between serum free light chains [dFLC]) >180 mg/L as an overall strong negative prognostic factor. Additionally, nephrotic-range albuminuria with an albumin-to-creatinine-ratio (ACR) >220 mg/mmol was a significantly adverse factor for hemEFS (hazard ratio, 2.1 and 3.1) with DD and DVD. Daratumumab salvage therapy produced good results and remission rates challenging any therapy in advanced AL. Outcome is adversely influenced by the activity of the underlying plasma cell dyscrasia (dFLC) and nephrotic-range albuminuria (ACR).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.